Current and future perspectives on lentiviral vector bioprocess and bioanalytical tools
Cell & Gene Therapy Insights 2021; 7(3), 367–372
Published: 4 May 2021
Paul Carter is the Head of Vector Processing at Quell Therapeutics Limited and has over 30 years’ experience in the pharmaceutical industry, working across cell and gene therapy, biopharmaceutical and small molecule R&D. Prior to joining Quell, he was leading GSK’s Downstream Process Development Group in Cell and Gene Therapy.